Why the study?
Therapeutic approaches for facioscapulohumeral dystrophy are entering clinical trials, creating a need to develop non-invasive biomarkers of disease activity and progression.
Population
Two independent cohorts of FSHD and control subjects
Comparison
FSHD subjects vs controls
Authors
Loading...
May support complement as FSHD biomarker; hypothesis-generating and requires prospective validation before clinical adoption.
Plasma complement components are elevated in patients with facioscapulohumeral dystrophy, suggesting potential utility as biomarkers for disease activity or therapeutic targets.
Wong et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: